MedTrace Logo

Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP)

NCT00793247 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2008-11-19

No results posted yet for this study

Summary

This study was designed to investigate the clinical safety, tolerability and efficacy of prucalopride in improving the symptoms associated with chronic intestinal pseudo-obstruction (CIP) in subjects with CIP. The study hypothesis was that prucalopride at doses up to 4 mg is safe, well tolerated, efficacious and improves the symptoms associated with CIP.

Conditions

  • Chronic Intestinal Pseudo-Obstruction

Interventions

DRUG

PRU-PLA-PRU-PLA

DRUG

PLA-PRU-PLA-PRU

DRUG

PLA-PRU-PRU-PLA

DRUG

PRU-PLA-PLA-PRU

Sponsors & Collaborators

  • Movetis

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00793247 on ClinicalTrials.gov